Approach to current therapeutic approaches in osteogenesis imperfecta based on the biology of the disease

Authors

  • Fabián Gómez-Ardila Orthopedics and Traumatology first-year resident, Fundación Universitaria Sánitas, Bogotá, Colombia.
  • Mauricio Lara-Garavito Orthopedics and Traumatology first-year resident, Fundación Universitaria Sánitas, Bogotá, Colombia.
  • César Álvarez-Quintero Pediatric orthopedist. Professor of Orthopedics and Traumatology, Fundación Universitaria Sánitas. | Orthopedist, Fundación Hospital de la Misericordia, Bogotá, Colombia. | Orthopedist, Clínica Universitaria Colombia, Bogotá, Colombia.

Keywords:

Osteogenesis Imperfecta, Bisphosphonates, Cell Therapy, Gene Therapy, Collagen Type I, Surgical Treatment

Abstract

Osteogenesis imperfecta is an inherited disease caused by alterations in the formation of collagen type 1 and characterized by bone fragility with a variable spectrum of clinical features, from fractures to bone deformities associated to perinatal death. The knowledge of the genetic alterations of this pathology should lead to the development of new therapeutic possibilities which are aimed to modify the natural course of the disease. Currently no treatment has been found to alter the course of the disease, so the efforts are aimed to improve patients’ bone quality, orthopedic and surgical treatment of fractures, and the multidisciplinary approach to improve patients’ environment. Some studies have made an approach to gene therapy and therapy with mesenchymal cells as an important option for treating these patients. This article aims to deepen into the biology of the disease, current treatment and to the possibilities of alternative therapies based on the molecular knowledge that cause clinical features.

Downloads

Download data is not yet available.

References

Arundel P, Bishop N. Diagnosing osteogenesis imperfecta. Paediatr Child Health 2010; 20(5): 225-31.

Burnei G, Vlad C, Georgescu I, Gavriliu T, Dan D. Osteogenesis imperfecta: diagnosing and treatment. J Am Acad Orthop Surg 2008;16: 356-66.

Lazala O. Osteogénesis imperfecta. Bogotá: Universidad Nacional de Colombia; 2004. p. 77-101.

Glorieux F. Osteogenesis imperfecta. Clinical Reumat 2008; 22(1):85-100.

Glorieux F, Rauch F. Osteogenesis imperfecta. En: Seibel MJ, Robins SP, Bilezikian JP. Dynamics of bone and cartilage metabolism. San Diego, California: Elsevier Inc.; 2006. p. 231-46.

Michel C, Vanisha P, Rouin A, Gargan M. Osteogenesis imperfecta. Curr Orthop 2007; 21: 236-41.

Chamberlain JR, Schwarze U, Hirata R. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004; 303:1198-201.

Millinigton-Ward S, McMahon H. Emerging therapeutic approaches for osteogenesis imperfecta. Trends Mol Med 2005; 11(6): 299-305.

Van Dijik F, Pals G, Van Rijnr. Classification of osteogenesis imperfecta revisited. Eur J Med Gen 2010; (53): 1-5.

DiMeglio L, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 132-40.

Carter E, Raggio C. Genetic and orthopedics aspects of collagen disorders. Curr Opin Pediatr 2009; 21(1): 46-54.

Morrissy RT, Weinstein SL, editores. Lovell and Winter’s pediatric orthopaedics. 5ª ed. Philadelphia: Lippincott Williams and Wilkins;2001.

Lazala O, Solaque H. Terapia con bifosfonatos en osteogénesis imperfecta. Rev Col Or Tra 2009; 23(2): 109-14.

Cheung F, Glorieaux M. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 2008; 9(2):153-60.

Pochampally R, Horwitz E, DiGirolamo C, Stokes D, Prockonp D. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Gene Ther 2005; 12:1119-25.

Phillipi CA, Remmington T, Steiner RD. Tratamiento con bifosfonatos para la osteogénesis imperfecta (revisión Cochrane traducida). Biblioteca Cochrane Plus 2008; (4). Consultado el 1 de febrero de 2011, desde: http://www.update-software.com/BCP/BCPGetDocument.asp?DocumentID=CD005088

Falk MJ, Heeger S, Lynch A. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-8.

Downloads

Published

2011-03-01

How to Cite

1.
Gómez-Ardila F, Lara-Garavito M, Álvarez-Quintero C. Approach to current therapeutic approaches in osteogenesis imperfecta based on the biology of the disease. Rev. Colomb. Ortop. Traumatol. [Internet]. 2011 Mar. 1 [cited 2026 Mar. 15];25(1):50-8. Available from: https://revistasccotorg.biteca.online/index.php/rccot/article/view/691

Issue

Vol. 25 No. 1 (2011)

Section

Original research

License

Copyright (c) 2025 Sociedad Colombiana de Ortopedia y Traumatología

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Escanea para compartir
QR Code